Nucleic acids and associated diagnostics
The present invention relates to methods of diagnosing spondylocostal dysostosis (SCD) disorders, such as Jarcho-Levin syndrome, in humans for use in genetic counseling and linkage analyses. Methods and compositions for measuring the presence or absence of a specific mutation to Mesp2 associated with Jarcho-Levin syndrome, alone or in combination with other mutations associated with spondylocostal dysostosis, are provided.
1. A method of identifying a human subject having a mutation associated with Jarcho-Levin syndrome comprising:
a) obtaining a biological sample from a human subject comprising genomic DNA of the human subject;
b) detecting in the genomic DNA substitution of a thymine for a guanine at nucleotide position 307 of exon 1 of Mesp2, whereby detection of the substitution is indicative of a mutation associated with Jarcho-Levin syndrome.
2. The method of claim 1 , wherein the biological sample is selected from the group consisting essentially of bodily fluid, epithelial cells, and a combination thereof.
3. The method of claim 1 , wherein detection is selected from the group consisting essentially of PCR-RFLP, ligase chain reaction (LCR), oligotyping using Sequence Specific Primers (SSP), oligotyping using Sequence Specific Oligonucleotide Probes (SSOP), single-stranded conformation polymorphism (SSCP), direct sequencing, restriction digest, single base pair primer extension, and a combination thereof.
4. The method of claim 3 , wherein detection comprises single base pair primer extension.
5. The method of claim 1 , further comprising detection of the presence or absence of a second mutation linked to spondylocostal dysostosis, wherein the second mutation is selected from the group consisting of 500-503 dup [MIM 605195.0001] in Mesp2, a mutation in DLL3, a mutation in Lfng, and a combination thereof.
6. A method of identifying a human subject having a thymine to guanine substitution at nucleotide position 307 of Exon 1 of Mesp2 comprising determining whether a nucleic acid obtained from a biological sample of the human subject has an E103 stop mutation.
7. The method according to claim 6 further comprising correlating the presence of an E103 stop mutation in a nucleic acid of the human subject with the human subject having Jarcho-Levin syndrome or being a carrier for Jarcho-Levin syndrome.
8. The method according to claim 6 , wherein the biological sample is selected from the group consisting essentially of bodily fluid, epithelial cells, and a combination thereof.
9. The method according to claim 6 , wherein the determining step is selected from the group consisting essentially of PCR-RFLP, ligase chain reaction (LCR), oligotyping using Sequence Specific Primers (SSP), oligotyping using Sequence Specific Oligonucleotide Probes (SSOP), single-stranded conformation polymorphism (SSCP), direct sequencing, restriction digest, single base pair primer extension, and a combination thereof.
10. The method according to claim 9 , wherein determining step comprises single base pair primer extension.
11. The method according to claim 6 , further comprising detecting of the presence or absence of a second mutation linked to spondylocostal dysostosis, wherein the second mutation is selected from the group consisting of 500-503 dup [MIM 605195.0001] in Mesp2, a mutation in DLL3, a mutation in Lfng, and a combination thereof.